Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (71)	5/31/1998 3:20:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 626

Rick: >>...much less an anti-idiotype against a self antigen.<< Than, is there any reasonable explanation for immune antibody response in TriAb and CeaVac vaccines PI/II trials, and clinical response for TriGem vaccine PI/II trial? I am not putting much of the TTNP value in their vaccines program, still will not like that this may be pressure for recent/future investor sell-of. There was some sell-of during ASCO hype and this may continue. Contrary is my opinion, TTNP value is in Iloperidone, Pivanex and Spheramine. Thanks. Miljenko

To: scaram(o)uche who wrote (71)	5/31/1998 4:20:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 626

Richard, You pose a great question, but the answer is beyond my realm of knowledge. I'm afraid any answer that I might pose would only confuse the issue. From talking with Titan, I get the impression that Iloperidone will be the catalyst that funds the company for their research with their various cancer programs. What intriques me about Titan is that this isn't a one product company. How often is it that we see a small biotech with all of their "eggs" in one basket and when their product fails(AMYLIN,Depotech,etc.)it is devastating for the company. Just for the newcomers to the thread, the following is a list of the various products that they have in development: 1) Iloperidone-treatment of schizophrenia in Phase III testing with alliance with Novartis. Novartis is picking up the tab for this testing. 2) CeaVac--an anti-idiotype antibody vaccine. Phase III study is to start in 1998 for colorectal cancer patients. 3) TriAB--an anti-idiotype antibody with a Phase II/III study in patients with breast cancer in 1998. 4) TriGem- an anti-idiotype antibody. Phase II/III test planned for patients with small cell lung cancer in 1998, and is also planning to begin pilot clinical studies in patients with psoriasis in 1998. 5) Pivanex--a cell differentiating agent. Phase II study in non-small cell lung cancer patients in 1998. 6) RB94-a tumor suppressor gene. Pilot clinical trials are planned in patients with prostate and bladder cancers in 1998. 7) MDRxI- a gene-based product to protect healthy bone marrow and blood cells from chemotheraphy toxicity. Additional pilot clinicals are planned. 8) Spheramine--cell-bsed therapeutic product for the treatment of Parkinson's disease. Human clinicals are planned for 1998. 9) Sertoli Cells- cell-based technology to promote neural regeneration. Has been tested succesfully in small animals. 10) Implantable Drug Delivery System--a platform drug delivery technology with applications to several neurologic and psychiatric disorders. Recently was shown to work in pilot animal studies. As you can see Titan has a lot going for it. The major issue is funding to support all of this research. When Iloperidone starts generating monies, this will be a big relief for Titan. I also like the caliber of the managment. They all have great expertise and come from companies like Hoechst Marion Roussel, Baayer, Amgen, Fresuenius and the CEO comes from Genentech. All of this for a $5.00 stock.(:>)